InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...
Northstrive Biosciences and Yuva Biosciences previously announced the AI Development Program, a collaboration leveraging MitoNova™, YuvaBio&rsquo...
CrystalsFirst GmbH, a leader in high-performance structural biology services, and NexMR AG, a pioneer in ultrafast NMR screening, announ...
Two leaders in lipid nanoparticle (LNP) development have partnered to make PEG-free shielding lipids available to researchers advancing LNPs for non-vira...
Gilead Sciences celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the co...
Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs Amgen announced plans to invest more than ...
Regenerex Pharma, Inc. (OTC: RGPX), a leading innovator in advanced wound closure systems for chronic wounds, today announced that it has entered into a ...
Quotient Sciences, a leading global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a memorandum of...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received orphan drug designation for anticancer ...
Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 phase 3 study that demonstrate...
Piramal Pharma Solutions extended its robust CDMO capabilities to George Medicines to develop WIDAPLIK. WIDAPLIK is the first and only FDA-approved tr...
CAGE Bio Inc., a leader in advancing innovative therapies for targeted and localized treatment of immunological skin diseases, today announced it has ent...
ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison. -...
© 2025 Biopharma Boardroom. All Rights Reserved.
